Engineering Immune Cells to Treat Cancers
August 23, 2018
AMSBIO produce a growing range of experimental cell lines, recombinant proteins and screening services to advance the search for new Chimeric Antigen Receptor (CAR T) cell therapies to treat cancers. For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last twenty years, therapeutic drugs that target cancer cells by homing in [...]
August 22, 2018
Shimadzu Corporation announces the release of IMAGEREVEAL MS mass spectrometry imaging data analysis software. The software simplifies the data analysis process by enabling data to be analyzed from a variety of perspectives, without requiring any extra time or trouble. It is especially well-suited to analyzing large sets of data or simultaneously analyzing multiple sets of [...]
Harvard Bioscience Announces Management Change
August 22, 2018
CFO Resigns to Pursue New Opportunity HOLLISTON, Mass. -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced the resignation of Robert E. Gagnon, Chief Financial Officer, effective August 31, 2018. The Company has initiated a search for its next chief financial officer. [...]
August 22, 2018
RESEARCH TRIANGLE PARK, N.C.--Cell Microsystems, a provider of innovative tools and scalable solutions for the sorting and isolation of single cells, announced today the first commercial sale of its automated AIR™ System for the imaging, sorting and isolation of single cells and small colonies. Albert Einstein College of Medicine investigator Jan Vijg, PhD, acquired the [...]
Easy to use Mass Directed Purification with Single Quadrupole Mass Spectrometer
August 22, 2018
KNAUER launched a single quadrupole mass spectrometer. With the KNAUER 4000 MiD® the Berlin-based company expands their preparative HPLC portfolio to the field of mass directed purification. The usage of mass spectrometry in the preparative HPLC enables the collection of target molecules according to their molecular mass. Natural products, pharmaceuticals, and other small organic molecules [...]
August 21, 2018
NEWARK, Calif. -- ATUM (formerly DNA2.0 Inc.), a pioneer in bioengineering solutions, announce the issuance of patent No. 10,041,077 by the U.S. Patent and Trademark Office (USPTO) for expanding the scope of Leap-In, the company's innovative transposon-based tool. The patent entitled "DNA vectors, transposons and transposases for eukaryotic genome modification," covers configurations of vectors and [...]
Swedish Government and GE Healthcare Open an Innovation Center for Life Sciences
August 21, 2018
Swedish biotech BioLamina relies on Testa Center to expand Chalfont St Giles, UK & Uppsala, Sweden – The Swedish government and GE Healthcare are opening Testa Center - an innovation center in Uppsala, Sweden, to boost the commercialization of new technologies and support manufacturing capabilities in the life sciences sector. The 2500 m2 (27,000 sq. ft.) Testa [...]
MBio Diagnostics, Inc. Announces Additional $6 Million in Series B Funding
August 21, 2018
BOULDER, Colo.--MBio Diagnostics, Inc., a company leading a new era in rapid, on-the-spot clinical diagnostics and sample testing, announced an additional $6 million in Series B financing led by new and existing investors, including MBio’s recently announced strategic veterinary partner, Heska. The funding supports the refinement of the MBio platform and improvements in manufacturing as [...]
Agilent Companion Diagnostic Gains Expanded FDA Approval in Urothelial Carcinoma
August 21, 2018
PD-L1 IHC 22C3 pharmDx Now Approved to Identify Certain Urothelial Carcinoma Patients for Treatment With KEYTRUDA(R) (pembrolizumab) SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now approved [...]
Recombinetics Closes $34 Million in Series A Funding
August 21, 2018
Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today announced the completion of a $34 million Series A financing round. “We’re pleased to announce the successful completion of our Series A Round,” said Tammy Lee, President and CEO of Recombinetics. “This financing will allow us to accelerate commercialization of this transformative science to [...]
